$EVOK
Evoke Pharma Inc

2019 Q4 Form 10-Q Financial Statement

#000156459019041384 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $780.0K $810.0K $1.070M
YoY Change -27.1% -10.0% 3.88%
% of Gross Profit
Research & Development $641.5K $822.4K $700.0K
YoY Change -8.35% 30.55% -57.1%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $641.5K $1.637M $1.770M
YoY Change -63.75% 7.68% 8.49%
Operating Profit -$1.637M
YoY Change 7.49%
Interest Expense $10.00K $8.597K $10.00K
YoY Change 0.0% 178.31%
% of Operating Profit
Other Income/Expense, Net $0.00 $8.597K $0.00
YoY Change 178.31% -100.0%
Pretax Income -$1.420M -$1.630M -$1.760M
YoY Change -19.32% 7.24% 467.74%
Income Tax
% Of Pretax Income
Net Earnings -$1.418M -$1.628M -$1.761M
YoY Change -19.45% 7.15% 470.81%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$58.41K -$67.55K -$101.0K
COMMON SHARES
Basic Shares Outstanding 24.23M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.660M $6.500M $5.320M
YoY Change 6.39% -1.07% -30.73%
Cash & Equivalents $5.664M $6.505M $5.319M
Short-Term Investments
Other Short-Term Assets $11.55K $330.0K
YoY Change -97.37% 32.0%
Inventory
Prepaid Expenses $581.7K $775.6K $329.2K
Receivables
Other Receivables
Total Short-Term Assets $6.246M $7.292M $5.648M
YoY Change 10.58% 4.02% -28.78%
LONG-TERM ASSETS
Property, Plant & Equipment $140.0K $40.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.55K $0.00 $11.55K
YoY Change 0.0% -100.0% 0.0%
Total Long-Term Assets $150.1K $35.40K $11.55K
YoY Change 1199.36% 253.98% 0.0%
TOTAL ASSETS
Total Short-Term Assets $6.246M $7.292M $5.648M
Total Long-Term Assets $150.1K $35.40K $11.55K
Total Assets $6.396M $7.327M $5.660M
YoY Change 13.0% 4.38% -28.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.030M $1.150M $480.0K
YoY Change 114.58% 82.54% -54.29%
Accrued Expenses $980.0K $1.000M $1.160M
YoY Change -15.52% 2.04% 12.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.015M $2.154M $1.634M
YoY Change 23.29% 33.8% -21.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.015M $2.154M $1.634M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.015M $2.150M $1.630M
YoY Change 23.62% 33.54% -71.78%
SHAREHOLDERS EQUITY
Retained Earnings -$85.73M -$84.31M -$78.60M
YoY Change 9.07% 10.65%
Common Stock $90.11M $89.49M $82.63M
YoY Change 9.05% 12.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.381M $5.173M $4.025M
YoY Change
Total Liabilities & Shareholders Equity $6.396M $7.327M $5.660M
YoY Change 13.0% 4.38% -28.73%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income -$1.418M -$1.628M -$1.761M
YoY Change -19.45% 7.15% 470.81%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.150M -$1.050M -$1.250M
YoY Change -8.0% -8.7% -54.38%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 310.0K 120.0K 0.000
YoY Change -89.92%
NET CHANGE
Cash From Operating Activities -1.150M -1.050M -1.250M
Cash From Investing Activities
Cash From Financing Activities 310.0K 120.0K 0.000
Net Change In Cash -840.0K -930.0K -1.250M
YoY Change -32.8% -2425.0% -54.38%
FREE CASH FLOW
Cash From Operating Activities -$1.150M -$1.050M -$1.250M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Assets Current
AssetsCurrent
5648222
CY2019Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
775607
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
329218
CY2019Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2019Q3 us-gaap Assets Current
AssetsCurrent
7291960
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
35398
CY2018Q4 us-gaap Assets
Assets
5659773
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
476202
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1158251
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1139720
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
2423
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Registrant Name
EntityRegistrantName
Evoke Pharma Inc
dei Entity Central Index Key
EntityCentralIndexKey
0001403708
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24231914
dei Entity File Number
EntityFileNumber
001-36075
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8447886
dei Entity Address Address Line1
EntityAddressAddressLine1
420 Stevens Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 370
dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
dei City Area Code
CityAreaCode
(858)
dei Local Phone Number
LocalPhoneNumber
345-1494
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2019Q3 us-gaap Assets
Assets
7327358
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1154520
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
964243
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
35398
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2154161
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1634453
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1743
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
89482936
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
82628312
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84312162
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2114096
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
331303
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24128060
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
380062
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
393775
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78604735
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
5173197
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4025320
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7327358
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5659773
us-gaap Operating Expenses
OperatingExpenses
5730295
us-gaap Operating Expenses
OperatingExpenses
6246265
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1636662
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1522557
us-gaap Operating Income Loss
OperatingIncomeLoss
-5730295
us-gaap Operating Income Loss
OperatingIncomeLoss
-6246265
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8597
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3089
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
22868
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7425
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-433392
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8597
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3089
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22868
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
440817
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1628065
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1519468
us-gaap Net Income Loss
NetIncomeLoss
-5707427
us-gaap Net Income Loss
NetIncomeLoss
-5805448
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17129649
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21623648
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16327385
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1965266
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3075445
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
6346146
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
331303
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
123813
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
2165749
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
544643
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1111349
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6567918
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3267885
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1982786
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
4389266
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
387429
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2886877
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2303194
us-gaap Share Based Compensation
ShareBasedCompensation
1161266
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
345975
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
187911
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
383896
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-464161
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4614403
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5729646
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5800201
CY2018Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
47057
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
5407749
us-gaap Share Based Compensation
ShareBasedCompensation
1055103
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4618297
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5800201
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4618297
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1185798
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7679267
evok Reclassification Of Warrant Liability To Equity Due To Amendment Of Warrants
ReclassificationOfWarrantLiabilityToEquityDueToAmendmentOfWarrants
3267885
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p>
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2019Q2 evok Minimum Common Stock Closing Bid Price Per Share
MinimumCommonStockClosingBidPricePerShare
1.00
CY2019Q2 evok Initial Period To Regain Compliance
InitialPeriodToRegainCompliance
P180D
CY2019Q2 evok Number Of Minimum Consecutive Business Days
NumberOfMinimumConsecutiveBusinessDays
10
evok Closing Bid Price Description
ClosingBidPriceDescription
On May 15, 2019, the Company received a letter from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq listing rules, the Company has been provided an initial period of 180 calendar days, or until November 11, 2019, to regain compliance. The letter states that Nasdaq will provide written notification that the Company has achieved compliance with its rules if at any time before November 11, 2019, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. The Nasdaq letter has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq Capital Market.
CY2018Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
25055
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5835226
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5733882
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5835226
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5758937
evok Lease Commencement Date
LeaseCommencementDate
2017-01-01
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2019-12-31
CY2019Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
36000
CY2018Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
35000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
109000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
104000
evok Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.12
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
136000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
136000
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.75
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
2456999
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1842746
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.62
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
84000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0

Files In Submission

Name View Source Status
0001564590-19-041384-index-headers.html Edgar Link pending
0001564590-19-041384-index.html Edgar Link pending
0001564590-19-041384.txt Edgar Link pending
0001564590-19-041384-xbrl.zip Edgar Link pending
evok-10q_20190930.htm Edgar Link pending
evok-20190930.xml Edgar Link completed
evok-20190930.xsd Edgar Link pending
evok-20190930_cal.xml Edgar Link unprocessable
evok-20190930_def.xml Edgar Link unprocessable
evok-20190930_lab.xml Edgar Link unprocessable
evok-20190930_pre.xml Edgar Link unprocessable
evok-ex311_8.htm Edgar Link pending
evok-ex312_7.htm Edgar Link pending
evok-ex321_6.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending